Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
APVO | US
0.04
20.35%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.24
0.23
0.45
0.21
Aptevo Therapeutics Inc. a clinical-stage biotechnology company focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436 a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527 an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4 a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603 a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711 a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442 a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle Washington.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
157.0%1 month
124.1%3 months
126.1%6 months
175.8%-
3.94
0.48
1.13
0.34
0.39
0.12
-
-25.52M
3.21M
3.21M
-
-
-
-100.00
-243.73
0.02
0.43
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.31
Range1M
0.31
Range3M
0.34
Rel. volume
18.18
Price X volume
37.27M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Virpax Pharmaceuticals Inc | VRPX | Biotechnology | 0.7216 | 3.53M | 6.15% | n/a | 0.00% |
Biodexa Pharmaceticals | BDRX | Biotechnology | 5.98 | 3.47M | 4.91% | n/a | 0.00% |
Alaunos Therapeutics Inc | TCRT | Biotechnology | 2.16 | 3.46M | -4.42% | n/a | 0.00% |
QNRX | QNRX | Biotechnology | 0.8646 | 3.44M | 1.72% | n/a | 43.11% |
22nd Century Group Inc | XXII | Biotechnology | 0.105 | 3.30M | 0.10% | n/a | -1072.15% |
Galera Therapeutics Inc | GRTX | Biotechnology | 0.0555 | 3.07M | 2.78% | n/a | -0.87% |
NovaBay Pharmaceuticals Inc | NBY | Biotechnology | 0.6211 | 3.03M | -1.38% | n/a | -325.77% |
Hiru Corporation | HIRU | Biotechnology | 0.0016 | 3.02M | -15.79% | n/a | 263.27% |
SciSparc Ltd. Ordinary Shares | SPRC | Biotechnology | 0.29 | 3.00M | 26.53% | n/a | 1.00% |
Ensysce Biosciences Inc | ENSC | Biotechnology | 0.206 | 2.86M | 15.86% | n/a | 24.79% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.39 | 0.53 | Cheaper |
Ent. to Revenue | 0.12 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.48 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 126.12 | 72.80 | Riskier |
Debt to Equity | 1.13 | -1.23 | Expensive |
Debt to Assets | 0.34 | 0.25 | Expensive |
Market Cap | 3.21M | 3.66B | Emerging |